MURATORE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.008
EU - Europa 2.092
AS - Asia 849
OC - Oceania 11
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 3
Totale 8.978
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.974
GB - Regno Unito 607
IT - Italia 541
SE - Svezia 345
CN - Cina 283
HK - Hong Kong 215
SG - Singapore 206
DE - Germania 157
UA - Ucraina 124
TR - Turchia 97
BG - Bulgaria 81
FI - Finlandia 79
FR - Francia 60
ID - Indonesia 21
BZ - Belize 20
NL - Olanda 19
LT - Lituania 18
BE - Belgio 14
IE - Irlanda 13
AU - Australia 10
CA - Canada 8
CZ - Repubblica Ceca 7
JP - Giappone 6
PT - Portogallo 6
CH - Svizzera 5
EU - Europa 5
CL - Cile 4
IN - India 4
IR - Iran 4
KR - Corea 4
MX - Messico 4
VN - Vietnam 4
AR - Argentina 3
ES - Italia 3
PL - Polonia 3
RU - Federazione Russa 3
AT - Austria 2
BR - Brasile 2
CU - Cuba 2
HU - Ungheria 2
MA - Marocco 2
BO - Bolivia 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
IL - Israele 1
KG - Kirghizistan 1
KZ - Kazakistan 1
NZ - Nuova Zelanda 1
RO - Romania 1
SA - Arabia Saudita 1
TH - Thailandia 1
Totale 8.978
Salva come PNG Salva come JPEG
Città #
Fairfield 1.025
Woodbridge 574
Ashburn 504
Houston 465
Southend 461
Chandler 438
Seattle 431
Wilmington 317
Cambridge 301
Ann Arbor 255
Nyköping 235
Hong Kong 215
Jacksonville 204
Dearborn 193
Modena 171
Singapore 143
New York 125
San Diego 101
Beijing 87
Princeton 78
Sofia 78
Eugene 51
Helsinki 45
Shanghai 43
San Jose 42
Milan 40
London 38
Izmir 36
Redwood City 29
Boardman 24
Jakarta 21
Belize City 20
Bologna 20
Chicago 15
Kilburn 15
Brussels 14
Dublin 13
Falls Church 13
Buffalo 12
Guangzhou 12
Norwalk 12
Reggio Emilia 12
Rome 12
Las Vegas 11
Munich 11
Reggio Nell'emilia 11
Bremen 10
Florence 10
Nanjing 10
Parma 10
Chiswick 8
Amsterdam 7
Hefei 7
Palermo 7
Trieste 7
Vigevano 7
Brno 6
Hounslow 6
Lappeenranta 6
Saint Louis 6
Ankara 5
Dallas 5
Dongguan 5
Kunming 5
Toronto 5
Washington 5
Andover 4
Arceto 4
Augusta 4
Brindisi 4
Columbus 4
Council Bluffs 4
Credaro 4
Dong Ket 4
Genoa 4
Los Angeles 4
Roccapalumba 4
San Mateo 4
Albuquerque 3
Bari 3
Bordighera 3
Catania 3
Catanzaro 3
Frankfurt am Main 3
Fuzhou 3
Jinan 3
Leawood 3
Montespertoli 3
Mykolayiv 3
Padova 3
Paris 3
Porto 3
Quzhou 3
Shenyang 3
Silver City 3
Verona 3
Wandsworth 3
Ardabil 2
Assago 2
Benevento 2
Totale 7.221
Salva come PNG Salva come JPEG
Nome #
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 189
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 188
Visual loss and other cranial ischaemic complications in giant cell arteritis 185
Biotherapies in large vessel vasculitis 181
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 181
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 177
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 177
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 174
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 170
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 170
Imaging of vasculitis: State of the art 170
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 166
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 164
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 164
Increased expression of interleukin-22 in patients with giant cell arteritis 161
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 161
Biologics in vasculitides: Where do we stand, where do we go from now? 160
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 160
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 158
Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease 157
L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats 155
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 154
Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? 152
Statin use in giant cell arteritis: a retrospective study 151
Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis 150
Large-vessel giant cell arteritis: a cohort study 146
Tocilizumab for the treatment of giant cell arteritis 145
Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis 144
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches 142
Unmet Needs in the Pathogenesis and Treatment of Vasculitides 142
Mycophenolate mofetil in primary central nervous system vasculitis 140
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? 138
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica 136
Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study 134
No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis 134
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab 134
L30. Assessment of vasculitis extent and severity 133
Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations 131
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 124
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study 118
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study 118
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma 118
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study 117
The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis 112
Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study 107
Extra-articular rheumatoid arthritis imaged by [18F]FDG-PET/CT 106
Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica 102
Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis 100
Isolated vasculitis of the lower extremities in a patient with polymyalgia rheumatica and giant cell arteritis 88
Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography 86
IgG4-associated sclerosing mesenteritis 86
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis 83
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 73
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 72
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 69
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 69
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients 65
Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy 57
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 56
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 56
Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells 55
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 54
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 54
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study 52
Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases 51
Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study 50
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study 50
Response to ‘The Relevance of Restricted Inflammation in a TAB’ by Griffin KJ et al 49
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 47
Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis 46
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 43
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 41
Response to: COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: A cross-sectional patient survey study' by Cuceoglu et al 40
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap? 39
Vasculitis, fibromuscular dysplasia or hereditary aneurysms? 39
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 39
Interleukin-6 expression in inflamed and non-inflamed temporal arteries from patients with giant cell arteritis 38
What to Know About Biopsy Sampling and Pathology in Vasculitis? 37
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 32
Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis 32
Updates on the diagnosis and monitoring of giant cell arteritis 30
Large-Vessel Vasculitis 29
Pathogenesis 25
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 24
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 24
Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases 21
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 19
Corrigendum to: Increased expression of interleukin-22 in patients with giant cell arteritis 19
FRI0212 THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS 17
Giant cell arteritis and its mimics: A comparison of three patient cohorts 16
The importance of defining which Janus kinases are activated in giant cell arteritis 11
Giant Cell Arteritis and Polymyalgia Rheumatica 10
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 9
Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis 9
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 9
The Role of PET in the Diagnosis and Disease Activity Assessment in Large Vessel Vasculitis 6
Role of miR-146a and miR-146b in Giant Cell Arteritis. 5
Reply 5
Systemic vasculitis: one year in review 2024 5
Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France 4
Totale 9.141
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.748 0 0 56 126 229 326 345 227 222 64 121 32
2020/20211.760 136 72 115 184 245 138 114 225 103 168 142 118
2021/20221.390 77 95 104 83 45 116 131 52 150 114 262 161
2022/20231.409 166 151 111 113 147 183 44 108 206 25 76 79
2023/20241.082 19 70 50 100 190 134 98 172 28 27 63 131
2024/2025219 138 48 33 0 0 0 0 0 0 0 0 0
Totale 9.187